CI3

Against the background of demographic development and the spread of cancer, autoimmune diseases and infections, the prevention, diagnosis and treatment of these severe common diseases will become very important topics for future health care. At the same time, the emerging trends towards individualised medicine and more preventive approaches pose a challenge for the entire health system.

The Cluster for Individualized ImmuneIntervention (CI3) meets these challenges with its specific problem-solving expertise. With more than 120 partners from universities, university clinics, research institutes and enterprises - including several of the world's leading pharmaceutical companies - CI3 develops efficient immune therapeutics with few side effects, as well as related diagnostic products for stratified and individualised markets. These new prevention, diagnosis and therapy options for severe common diseases will be validated for their future viability and sustainability and made available for health care.

The three CI3 landmark projects focus on research into both stratified and individualised vaccines for the treatment of solid cancers, as well as on novel therapeutic agents to treat coeliac disease.

The main objective of the cluster is to bundle the outstanding expertise in the Rhine-Main cluster region in the area of medicinal products, therapeutic approaches and diagnostics in the field of individualised immune intervention and to establish the cluster region among the international leaders.